Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Nimotuzumab, as one new agent used in advanced esophageal carcinoma, has been shown to be
effective and safe in some studies with head-neck cancers. Advanced esophageal carcinoma have
poor prognosis and majority of patients resistant to chemotherapy in China. In the
investigators phase II clinical trial proceeded before,the combination of paclitaxel with
cisplatin showed good tolerance and efficacy to esophageal carcinoma. The investigators then
initiated a prospective phase II clinical trial with Nimotuzumabplus paclitaxel/cisplatin as
the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of
the combination.